Memory Pharmaceuticals Highlights Progress With Key Programs At Its R&D Day

Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound’s CNS activity in humans. In addition, the Company has nominated MEM 68626 as the lead development candidate from its 5-HT6 antagonist program, and separately confirmed its 2008 development goals for its pipeline.

More: continued here

Filed under: Cancer on May 17th, 2008